JP5646617B2 - 多発性硬化症の治療のための組成物および方法 - Google Patents

多発性硬化症の治療のための組成物および方法 Download PDF

Info

Publication number
JP5646617B2
JP5646617B2 JP2012516022A JP2012516022A JP5646617B2 JP 5646617 B2 JP5646617 B2 JP 5646617B2 JP 2012516022 A JP2012516022 A JP 2012516022A JP 2012516022 A JP2012516022 A JP 2012516022A JP 5646617 B2 JP5646617 B2 JP 5646617B2
Authority
JP
Japan
Prior art keywords
multiple sclerosis
treatment
composition
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012516022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530132A (ja
Inventor
ゲルダー，フランク，ビー．
ウェブスター，ジリアン，アリソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Immunotherapeutics Ltd
Original Assignee
Innate Immunotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Immunotherapeutics Ltd filed Critical Innate Immunotherapeutics Ltd
Publication of JP2012530132A publication Critical patent/JP2012530132A/ja
Application granted granted Critical
Publication of JP5646617B2 publication Critical patent/JP5646617B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Photographic Developing Apparatuses (AREA)
JP2012516022A 2009-06-16 2010-06-16 多発性硬化症の治療のための組成物および方法 Expired - Fee Related JP5646617B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis
NZ5777731 2009-06-16
PCT/NZ2010/000112 WO2010147484A1 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
JP2012530132A JP2012530132A (ja) 2012-11-29
JP5646617B2 true JP5646617B2 (ja) 2014-12-24

Family

ID=42646236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012516022A Expired - Fee Related JP5646617B2 (ja) 2009-06-16 2010-06-16 多発性硬化症の治療のための組成物および方法

Country Status (20)

Country Link
US (1) US8389479B2 (enExample)
EP (1) EP2442832B1 (enExample)
JP (1) JP5646617B2 (enExample)
CN (1) CN102458476B (enExample)
AU (1) AU2010260585B2 (enExample)
BR (1) BRPI1009606A2 (enExample)
CA (1) CA2688766C (enExample)
CY (1) CY1115714T1 (enExample)
DK (1) DK2442832T3 (enExample)
ES (1) ES2521565T3 (enExample)
HR (1) HRP20141035T1 (enExample)
IL (1) IL216993A (enExample)
IN (1) IN2012DN00167A (enExample)
MX (1) MX2011013661A (enExample)
NZ (1) NZ577731A (enExample)
PL (1) PL2442832T3 (enExample)
PT (1) PT2442832E (enExample)
SI (1) SI2442832T1 (enExample)
SM (1) SMT201400165B (enExample)
WO (1) WO2010147484A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103990120B (zh) * 2008-04-01 2018-06-05 伊耐特免疫治疗有限公司 抗感染剂及其用途
EP3722808B1 (en) * 2010-10-25 2024-09-11 Biogen MA Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CA2926507A1 (en) * 2015-10-06 2017-04-06 Innate Immunotherapeutics Limited Compositions and methods for protection and/or repair of the nervous system
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
WO2019218079A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
WO2020010221A1 (en) * 2018-07-03 2020-01-09 University Of Florida Research Foundation, Inc. Microparticle systems and their use for the treatment of multiple sclerosis
BR112022024966A2 (pt) * 2020-06-22 2023-01-03 Otivio As Métodos para tratar espasticidade usando composições antiespasmódicas e terapia de pressão negativa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU732809B2 (en) * 1996-10-10 2001-05-03 Innate Immunotherapeutics Limited Compositions and methods for treating viral infections
EA200700263A1 (ru) * 2004-07-01 2007-06-29 Кебенхавнс Университет Способ лечения и профилактики рассеянного склероза путём лечения лептоспирозной инфекции
WO2008070564A1 (en) 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
JP2008251608A (ja) 2007-03-29 2008-10-16 Casio Comput Co Ltd 半導体装置およびその製造方法
WO2008150182A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treatment of anthrax
WO2008150181A1 (en) 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treating anthrax exposure associated conditions

Also Published As

Publication number Publication date
WO2010147484A1 (en) 2010-12-23
AU2010260585B2 (en) 2013-02-21
CY1115714T1 (el) 2017-01-25
ES2521565T3 (es) 2014-11-12
US20100317589A1 (en) 2010-12-16
IN2012DN00167A (enExample) 2015-04-17
AU2010260585A1 (en) 2012-01-19
EP2442832A1 (en) 2012-04-25
EP2442832A4 (en) 2013-07-03
US8389479B2 (en) 2013-03-05
SI2442832T1 (sl) 2014-12-31
JP2012530132A (ja) 2012-11-29
SMT201400165B (it) 2015-01-15
WO2010147484A8 (en) 2012-07-19
HK1167101A1 (en) 2013-02-01
BRPI1009606A2 (pt) 2016-10-11
CN102458476A (zh) 2012-05-16
EP2442832B1 (en) 2014-08-06
PT2442832E (pt) 2014-11-11
CA2688766C (en) 2015-06-30
DK2442832T3 (da) 2014-11-10
AU2010260585A8 (en) 2012-06-14
HRP20141035T1 (hr) 2014-12-19
IL216993A0 (en) 2012-02-29
CN102458476B (zh) 2014-08-20
MX2011013661A (es) 2012-05-22
PL2442832T3 (pl) 2015-01-30
CA2688766A1 (en) 2010-12-16
IL216993A (en) 2016-03-31
NZ577731A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
AU2010260585B2 (en) Compositions and methods for treatment of Multiple Sclerosis
Manjunatha et al. Multiple sclerosis: therapeutic strategies on the horizon
TWI643614B (zh) 低頻率格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之治療
JP6208235B2 (ja) 多発性硬化症治療のためのビオチンの使用
IL130820A (en) Pharmaceutical preparations for the oral treatment of multiple sclerosis
US20230331834A1 (en) Method of treating tendinopathy using interleukin-17 (il-17)
KR20170131543A (ko) 근위축성 측삭 경화증을 치료하기 위한 비오틴
KR20200101948A (ko) 신경계 질환 치료제
TW201204360A (en) Treatment of multiple sclerosis with MASITINIB
ES2447829T3 (es) Combinación para el tratamiento de la osteoartritis
TWI808397B (zh) 治療牛皮癬之方法
EA028448B1 (ru) Способ снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом, и набор для титрования для снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом
CN111803487B (zh) 银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途
KR100601080B1 (ko) (-)-에피갈로카테킨 갈레이트를 유효성분으로 하는류마티스성 관절염 치료제
KR101226605B1 (ko) 질병의 치료
HK1167101B (en) Compositions and methods for treatment of multiple sclerosis
JP6969790B2 (ja) マルチペプチド組成物
CN109999179A (zh) 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用
AU2009274022B2 (en) Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis
Bubna IL-17 Antagonists
WO2007105910A1 (en) A pharmaceutical composition for the treatment of allergic diseases and chronic inflammatory diseases, and a method for treatment of allergic diseases and chronic inflammatory diseases
Shome et al. Indrashis Podder, Sabari Bhattacharya, Vivek Mishra, Tushar Kanti Sarkar, Somodyuti Chandra, Amrita Sil1, Santasmita Pal2, Dhiraj Kumar, Abanti Saha
WO2012110946A1 (en) Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate
EA014287B1 (ru) Способ лечения заболевания двигательных нейронов козьей сывороткой

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140909

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141014

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141105

R150 Certificate of patent or registration of utility model

Ref document number: 5646617

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees